BioInvent International (BINV.ST) Osake Kurssi
BioInvent International Kurssi
Viimeisten 19 vuoden aikana BioInvent Internationaln liikevaihto kasvoi 8,2 % vuodessa ja ylsi 226,50 M SEK:een. BioInvent Internationaln nettomarginaali −147,0 % on noussut verrattuna −1 439,1 %:iin muutama vuosi sitten. BioInvent Internationaln 12 kuukauden konsensustavoitehinta on 91,80 SEK, noin yli kurssia 295,7 %. 9 analyytikosta 8 suosittaa ostoa — kokonaiskonsensus on Osta.
BioInvent International osakekurssi
BioInvent International liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset BioInvent International -osakkeesta
The business model of BioInvent International AB revolves around the discovery and development of innovative antibody-based immunotherapies. As a biopharmaceutical company, BioInvent focuses on identifying and targeting cancer and immune-mediated inflammatory diseases. Through its strong expertise in antibody research and proprietary antibody library, the company aims to develop novel drug candidates and partner with pharmaceutical companies for further clinical development and commercialization. By leveraging its unique technology platforms, BioInvent strives to provide effective and safe therapies to patients in need, while also generating value for its shareholders and partners.
BioInvent International AB is primarily active in the biotechnology industry.
The main competitors of BioInvent International AB in the market include other biotechnology companies that operate within the same therapeutic area and focus on the development of antibody-based therapeutics. Some notable competitors of BioInvent International AB may include Genmab A/S, MorphoSys AG, and Novartis AG. These competitors also strive to advance innovative solutions for diseases and disorders through research, development, and commercialization of antibody-based drugs. BioInvent International AB positions itself as a leading player in the field, continuously aiming to meet the evolving needs of patients and contribute to the growth of the biotech industry.
BioInvent International AB is a leading biotech company based in Sweden. Founded in 1987, BioInvent focuses on discovering and developing innovative antibody-based drugs for cancer treatment. With a rich history of over three decades, the company has gained expertise and recognition in the field of immuno-oncology. BioInvent collaborates with pharmaceutical partners to advance its proprietary antibody library, F.I.R.S.T™, and to accelerate the development of novel therapeutics. Through its innovative research and development efforts, BioInvent aims to improve patient outcomes and transform the treatment landscape for cancer. The company's commitment to scientific excellence and strategic partnerships has positioned it as a key player in the biopharmaceutical industry.
BioInvent International AB has achieved several significant milestones in its trajectory. The company successfully advanced its lead product candidate, BI-1206, into clinical trials. Furthermore, BioInvent International AB has established strategic collaborations with renowned pharmaceutical companies, including Pfizer and AstraZeneca, facilitating the development of innovative therapeutic antibodies. The company continues to demonstrate its commitment to research and development, expanding its pipeline and enhancing its expertise in the field of immuno-oncology. With a strong focus on strategic partnerships and an impressive track record, BioInvent International AB is well-positioned for future growth and success in the biopharmaceutical industry.
BioInvent International AB is primarily present in Sweden, where it is headquartered. As a biotech company, it focuses on the research and development of novel antibody-based drugs. Its operations encompass a global reach, collaborating with partners and clients across various countries and regions. However, in terms of primary presence and operations, BioInvent International AB is mainly concentrated in Sweden.
BioInvent International AB is a renowned biotech company committed to transforming the treatment of cancer. With a strong corporate philosophy focused on innovation and collaboration, BioInvent strives to deliver ground-breaking antibody-based therapies. The company's core values revolve around scientific excellence, integrity, and patient-centricity. BioInvent harnesses its unique antibody development platform to target and neutralize tumor antigens, leveraging its expertise in antibody engineering and immuno-oncology research. By prioritizing cutting-edge science and strategic partnerships, BioInvent seeks to address unmet medical needs and improve outcomes for cancer patients worldwide.
Analyytikot asettavat tällä hetkellä BioInvent International-osakkeelle keskimääräisen tavoitehinnan 81,60 SEK (mediaani: 91,80 SEK), mikä merkitsee +251,7 % viimeisimpään hintaan verrattuna. Konsensus perustuu 9 analyytikkoarvioon.
9 analyytikkoa arvioi tällä hetkellä BioInvent International-osaketta: 8 suosittaa ostoa, 1 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat BioInvent International-yhtiöltä 275,64 M SEK liikevaihtoa ja −7,03 SEK osakekohtaista tulosta.
Nykyisellä valuuttakurssilla BioInvent International-osake noteerataan hintaan 2,07 EUR (23,20 SEK).
BioInvent International-osake (BINV.ST) on listattuna 7 pörssissä, muun muassa: London (0H22.L), Frankfurt (BIX0.F), München (BIX0.MU), Düsseldorf (BIX0.DU), Stockholm (BINV.ST).
BioInvent International AB is a biotechnology company based in Lund, Sweden, that focuses on the research and development of antibody therapies. The company's business model is based on the discovery, development, and commercialization of antibodies for the treatment of cancer and other serious diseases. BioInvent operates in three business areas - research and development, therapeutic antibody production and manufacturing, and collaboration and licensing. The company's products include the antibody therapies BI-505 and BI-1206. BI-505 is currently in Phase II studies for the treatment of multiple myeloma patients, and BI-1206 is currently in Phase I studies for the treatment of advanced solid tumors including lung, colorectal, and ovarian cancers. The company's business model is focused on developing innovative antibody therapies that meet the needs of cancer patients, and it works closely with partners to ensure rapid progress in research and development while meeting regulatory requirements. BioInvent is a leading company in the development of antibody therapies and has a promising future in expanding treatment options for cancer patients.
odotettu liikevaihto BioInvent International on 275,64 M SEK. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto BioInvent International on −463,28 M SEK. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
BioInvent International:n hinta-voitto-suhde (P/E) on tällä hetkellä −3,30. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan BioInvent International-osakkeen arvostusta.
BioInvent International:n hinta-myynti-suhde (P/S) on tällä hetkellä 5,54. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii BioInvent International-osakkeen arvostuskennuslukuna.
BioInvent International:n Eulpool-laatuscore on 3/10.
BioInvent International:n ISIN on SE0015244520. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
BioInvent International:n WKN on A2QJRW. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
BioInvent International:n ticker on BINV.ST. Tämä pörssinoteeraus käytetään BioInvent International-osakkeiden kauppaan pörssissä.
BioInvent International osake
BioInvent International vertaisryhmä
BioInvent International Ticker
BioInvent International FIGI
Kaikki tunnusluvut ja syvällinen analyysi BioInvent International:sta
Meidän osakeanalyysimme BioInvent International-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut BioInvent International:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: